Lanean...
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Gemtuzumab ozogamicin (GO, Mylotarg(®)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials...
Gorde:
| Argitaratua izan da: | Int J Mol Sci |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7460695/ https://ncbi.nlm.nih.gov/pubmed/32781546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21165626 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|